天然硫辛酸是自然醫學的萬靈丹

天然硫辛酸是自然醫學的萬靈丹

<健康之音>如何收聽與Call In，在這裡有詳細說明:

http://www.vow99.org

如果說類固醇是現代西醫的美國仙丹，那麼，天然硫辛酸就是現代自然醫學的萬靈丹。

以下摘選自<發炎，並不件壞事>第160-161頁

 

硫辛酸總結有以下功能

還原其它的抗氧化劑(維生素C、維生素E、穀胱甘肽、輔酶Q10)保護心臟、預防腦中風、治療腦中風後遺症、預防老年失智症、穩定血糖、提高能量、消除疲勞、增強記憶力、促進末梢循環、預防肌膚老化、減少皺紋、預防白內障、抑制腫瘤基因、螯合重金屬以排出體外等等。

 

適合使用硫辛酸的疾病包括

糖尿病、急慢性肝病、肝硬化、肝昏迷、脂肪肝、心臟病、腦中風、動脈硬化、愛滋病、牛皮癬、濕疹、多發性硬化、類風濕性關節炎、紅斑性狼瘡、硬皮症、白內障、視網膜病變、燒燙傷、帕金森氏症、老年失智症。

以下硫辛酸功效與研究報告節選自維基百科http://en.wikipedia.org/wiki/Lipoic_acid

 Lipoic acid has been the subject of numerous research studies and clinical trials:

  • Prevent organ dysfunction[37]
  • Reduce endothelial dysfunction and improve albuminuria[38][39]
  • Treat or prevent cardiovascular disease[40]
  • Accelerate chronic wound healing[41]
  • Reduce iron overload[46]
  • Improve or prevent age-related cognitive dysfunction[50][51]
  • Prevent or slow the progression of Alzheimer’s Disease[52][53][54]
  • Prevent erectile dysfunction (animal models but anecdotally applies to humans as well)[55][56]
  • Prevent migraines[57]
  • Treat chronic diseases associated with oxidative stress[61]
  • Reduce inflammation[62]
  • Treat peripheral artery disease.[64]

·         ·

·         ·  ^ Gianturco, V, Bellomo, A, D’ottavio, E, Formosa, V, Iori, A, Mancinella, M, Troisi, G, Marigliano, V (2009). “Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction?”. Archives of gerontology and geriatrics 49 (Suppl 1): 129–33. doi:10.1016/j.archger.2009.09.022. PMID 19836626.

·         ·  ^ Morcos, M, Borcea, V, Isermann, B, Gehrke, S, Ehret, T, Henkels, M, Schiekofer, S, Hofmann, M et al (June 2001). “Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study”. Diabetes research and clinical practice 52 (3): 175–83. doi:10.1016/S0168-8227(01)00223-6. PMID 11323087.

·         ·  ^ Vossler, S, Füllert, S, Schneider, F, Haak, E, Haak, T, Samigullin, R, Tritschler, H, Tooke, JE et al (July 2007). “Pharmacodynamic effects of orally administered dexlipotam on endothelial function in type 2-diabetic patients”. International journal of clinical pharmacology and therapeutics 45 (7): 385–93. PMID 17725245.

·         ·  ^ Ghibu, S, Richard, C, Vergely, C, Zeller, M, Cottin, Y, Rochette, L (November 2009). “Antioxidant properties of an endogenous thiol: Alpha-lipoic acid, useful in the prevention of cardiovascular diseases”. Journal of cardiovascular pharmacology 54 (5): 391–8. doi:10.1097/FJC.0b013e3181be7554. PMID 19998523.

·         ·  ^ Alleva, R, Nasole, E, Di Donato, F, Borghi, B, Neuzil, J, Tomasetti, M (July 2005). “alpha-Lipoic acid supplementation inhibits oxidative damage, accelerating chronic wound healing in patients undergoing hyperbaric oxygen therapy”. Biochemical and biophysical research communications 333 (2): 404–10. doi:10.1016/j.bbrc.2005.05.119. PMID 15950945.

·         ·  ^ Chang, JW, Lee, EK, Kim, TH, Min, WK, Chun, S, Lee, KU, Kim, SB, Park, JS (2007). “Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study”. American journal of nephrology 27 (1): 70–4. doi:10.1159/000099035. PMID 17259696.

·         ·  ^ Femiano, F, Scully, C, Gombos, F (December 2002). “Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy”. International journal of oral and maxillofacial surgery 31 (6): 625–8. doi:10.1054/ijom.2002.0276. PMID 12521319.

·         ·  ^ Femiano, F, Scully, C (May 2002). “Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy”. Journal of Oral Pathology & Medicine 31 (5): 267–9. doi:10.1034/j.1600-0714.2002.310503.x. PMID 12110042.

·         ·  ^ Patton, LL, Siegel, MA, Benoliel, R, De Laat, A (March 2007). “Management of burning mouth syndrome: systematic review and management recommendations”. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 103 (Suppl): S39.e1–13. doi:10.1016/j.tripleo.2006.11.009. PMID 17379153.

·         ·  ^ Kundiev, IuI, Lubianova, IP, Mikhaĭlik, OM, Dudchenko, NO, Lampeka, EG (2001). “Berlition R 300 oral — alpha-lipoic acid preparation for the correction of body changes associated with high serum iron content”. Meditsina truda i promyshlennaia ekologiia (1): 14–8. PMID 11221104.

·         ·  ^ Sola, S, Mir, MQ, Cheema, FA, Khan-Merchant, N, Menon, RG, Parthasarathy, S, Khan, BV (January 2005). “Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study”. Circulation 111 (3): 343–8. doi:10.1161/01.CIR.0000153272.48711.B9. PMID 15655130.

·         ·  ^ Minokoshi, Y, Alquier, T, Furukawa, N, Kim, YB, Lee, A, Xue, B, Mu, J, Foufelle, F et al (April 2004). “AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus”. Nature 428 (6982): 569–74. doi:10.1038/nature02440. PMID 15058305.

·         ·  ^ Ying, Z, Kherada, N, Farrar, B, Kampfrath, T, Chung, Y, Simonetti, O, Deiuliis, J, Desikan, R et al (January 2010). “Lipoic acid effects on established atherosclerosis”. Life sciences 86 (3–4): 95–102. doi:10.1016/j.lfs.2009.11.009. PMC 3075920. PMID 19944706.

·         ·  ^ Liu, J (January 2008). “The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview”. Neurochemical research 33 (1): 194–203. doi:10.1007/s11064-007-9403-0. PMID 17605107.

·         ·  ^ Packer, L, Tritschler, HJ, Wessel, K (1997). “Neuroprotection by the metabolic antioxidant alpha-lipoic acid”. Free radical biology & medicine 22 (1–2): 359–78. doi:10.1016/S0891-5849(96)00269-9. PMID 8958163.

·         ·  ^ Holmquist, L, Stuchbury, G, Berbaum, K, Muscat, S, Young, S, Hager, K, Engel, J, Münch, G (January 2007). “Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias”. Pharmacology & therapeutics 113 (1): 154–64. doi:10.1016/j.pharmthera.2006.07.001. PMID 16989905.

·         ·  ^ Hager, K, Kenklies, M, McAfoose, J, Engel, J, Münch, G (2007). “Alpha-lipoic acid as a new treatment option for Alzheimer’s disease—a 48 months follow-up analysis”. Journal of neural transmission. Supplementum (72): 189–93. PMID 17982894.

·         ·  ^ MacZurek, A, Hager, K, Kenklies, M, Sharman, M, Martins, R, Engel, J, Carlson, DA, Münch, G (2008). “Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease”. Advanced drug delivery reviews 60 (13–14): 1463–70. doi:10.1016/j.addr.2008.04.015. PMID 18655815.

·         ·  ^ Hurdag, C, Ozkara, H, Citci, S, Uyaner, I, Demirci, C (2005). “The effects of alpha-lipoic acid on nitric oxide synthetase dispersion in penile function in streptozotocin-induced diabetic rats”. International journal of tissue reactions 27 (3): 145–50. PMID 16372481.

·         ·  ^ Yao, LS, Wang, YT, Chen, Y, Dai, YT (October 2009). “Expressions of NOS isoforms in the cavernous tissues of diabetic rat models”. Zhonghua nan ke xue = National journal of andrology 15 (10): 915–9. PMID 20112741.

·         ·  ^ Magis, D, Ambrosini, A, Sándor, P, Jacquy, J, Laloux, P, Schoenen, J (January 2007). “A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis”. Headache 47 (1): 52–7. doi:10.1111/j.1526-4610.2006.00626.x. PMID 17355494.

·         ·  ^ Yadav, V, Marracci, G, Lovera, J, Woodward, W, Bogardus, K, Marquardt, W, Shinto, L, Morris, C et al (April 2005). “Lipoic acid in multiple sclerosis: a pilot study”. Multiple sclerosis (Houndmills, Basingstoke, England) 11 (2): 159–65. doi:10.1191/1352458505ms1143oa. PMID 15794388.

·         ·  ^ Salinthone, S, Yadav, V, Bourdette, DN, Carr, DW (June 2008). “Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS”. Endocrine, metabolic & immune disorders drug targets 8 (2): 132–42. doi:10.2174/187153008784534303. PMID 18537699.

·         ·  ^ Yadav, V, Marracci, GH, Munar, MY, Cherala, G, Stuber, LE, Alvarez, L, Shinto, L, Koop, DR et al (April 2010). “Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters”. Multiple sclerosis (Houndmills, Basingstoke, England) 16 (4): 387–97. doi:10.1177/1352458509359722. PMID 20150394.

·         ·  ^ Smith, AR, Shenvi, SV, Widlansky, M, Suh, JH, Hagen, TM (May 2004). “Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress”. Current medicinal chemistry 11 (9): 1135–46. PMID 15134511.

·         ·  ^ Zhang WJ, Wei H, Hagen T, Frei B (2007). “α-Lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway”. Proc Natl Acad Sci U S A. 104 (10): 4077–82. doi:10.1073/pnas.0700305104. PMC 1805485. PMID 17360480.

·         ·  ^ Vasdev, S, Gill, V, Singal, P (2007). “Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications”. Cell biochemistry and biophysics 49 (1): 48–63. doi:10.1007/s12013-007-0039-0. PMID 17873339.

·         ·  ^ Vincent, HK, Bourguignon, CM, Vincent, KR, Taylor, AG (June 2007). “Effects of alpha-lipoic acid supplementation in peripheral arterial disease: a pilot study”. Journal of alternative and complementary medicine 13 (5): 577–84. doi:10.1089/acm.2007.6177. PMID 17604563.

 

瀏覽人次: 250